Amanote Research
Register
Sign In
Inhibitor Recognition Specificity of MERS-CoV Papain-Like Protease May Differ From That of SARS-CoV
doi 10.1021/cb500917m.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
In Silico Repositioning for Dual Inhibitor Discovery of SARS-CoV-2 (COVID-19) 3c-Like Protease and Papain-Like Peptidase
Characteristics of Flavonoids as Potent MERS ‐CoV 3C‐like Protease Inhibitors
Chemical Biology and Drug Design
Biochemistry
Organic Chemistry
Drug Discovery
Molecular Medicine
Pharmacology
Synonymous and Biased Codon Usage by MERS CoV Papain-Like and 3cl-Proteases
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Inhibition of SARS-CoV 3CL Protease by Flavonoids
Journal of Enzyme Inhibition and Medicinal Chemistry
Medicine
Drug Discovery
Pharmacology
Inhibition of SARS-CoV 3c-Like Protease Activity by Theaflavin-3,3'-Digallate (TF3)
Evidence-based Complementary and Alternative Medicine
Alternative Medicine
Complementary
In-Depth Bioinformatic Analyses of Human SARS-CoV-2, SARS-CoV, MERS-CoV, and Other Nidovirales Suggest Important Roles of Noncanonical Nucleic Acid Structures in Their Lifecycles
MERS-Cov and Immunobioinformatics
Journal of Medical Microbiology & Diagnosis
Potential Host Range of Multiple SARS-like Coronaviruses and an Improved ACE2-Fc Variant That Is Potent Against Both SARS-CoV-2 and SARS-CoV-1
MERS-CoV: In Search of Answers
The Lancet
Medicine
